Charting Human Cellular Senescence in Aging and Disease

Why It Matters

A comprehensive, organ‑level map of senescence enables precise biomarkers and targeted senolytic therapies, accelerating the shift from treating age‑related disease to preventing it. This knowledge base could transform drug development and clinical strategies for aging populations.

Key Takeaways

• SenNet creates multi‑omics atlas of senescent cells across 20+ human tissues
• Single‑cell and spatial omics reveal tissue‑specific senotypes and SASP diversity
• Circulating senescence signatures predict kidney disease, diabetes, and frailty
• AI‑driven analyses improve detection of rare senescent cell populations
• Senolytic candidates like α‑eleostearic acid extend healthspan in mouse studies

Pulse Analysis

The SenNet consortium represents a watershed moment in aging research, uniting dozens of tissue‑mapping centers to generate a unified, multimodal atlas of cellular senescence. Leveraging single‑cell RNA‑seq, spatial transcriptomics, proteomics and cutting‑edge AI, the project charts senescent cell distribution from the brain to the skin, exposing a mosaic of senotypes that differ by tissue, trigger and age. This granular view resolves long‑standing uncertainties about which cells become senescent in vivo and how their secretory phenotypes reshape local microenvironments.

Beyond mapping, SenNet’s open‑access SenCat database and plasma‑based senescence signatures are already informing biomarker pipelines. Studies linking renal epithelial senescence signatures to chronic kidney disease, or immune‑cell senescence to diabetes risk, illustrate how circulating markers can forecast disease trajectories before clinical onset. AI‑enhanced differential expression tools further sharpen detection of rare senescent populations, reducing false positives that have hampered earlier efforts. The integration of spatial context with multi‑omics data also clarifies how senescent cells interact with immune infiltrates, fibroblasts and endothelial networks, offering mechanistic insights into fibrosis, tumor progression and wound healing.

Therapeutically, the atlas fuels a new generation of senolytics tailored to specific senotypes. Preclinical work showing that α‑eleostearic acid induces ferroptosis in diverse senescent cells and improves metabolic health in obese mice underscores the promise of precision senolysis. As the consortium expands its tissue coverage and refines AI pipelines, the field moves toward interventions that can selectively clear harmful senescent cells while preserving beneficial ones, potentially extending healthspan and reducing the burden of age‑related diseases. The SenNet blueprint thus sets the stage for a proactive, data‑driven approach to aging medicine.